• Find People
  • Campus Map
  • PiratePort
  • A-Z
    • About
    • Submit
    • Browse
    • Login
    View Item 
    •   ScholarShip Home
    • Other Campus Research
    • Open Access
    • View Item
    •   ScholarShip Home
    • Other Campus Research
    • Open Access
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of The ScholarShipCommunities & CollectionsDateAuthorsTitlesSubjectsTypeDate SubmittedThis CollectionDateAuthorsTitlesSubjectsTypeDate Submitted

    My Account

    Login

    Statistics

    View Google Analytics Statistics

    Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents

    Thumbnail
    View/ Open
    Preclinical_and_Clinical_Asses.PDF (373.9Kb)

    Show full item record
    Author
    Ladin, Daniel; Soliman, Eman; Griffin, LaToya; Van Dross, Rukiyah
    Abstract
    Cancer is the second leading cause of death in the United States with 1.7 million new cases estimated to be diagnosed in 2016. This disease remains a formidable clinical challenge and represents a substantial financial burden to the US health care system. Therefore, research and development of novel therapeutics for the treatment of cancer is of high priority. Cannabinoids and their derivatives have been utilized for their medicinal and therapeutic properties throughout history. Cannabinoid activity is regulated by the endocannabinoid system (ECS), which is comprised of cannabinoid receptors, transporters, and enzymes involved in cannabinoid synthesis and breakdown. More recently, cannabinoids have gained special attention for their role in cancer cell proliferation and death. However, many studies investigated these effects using in vitro models which may not adequately mimic tumor growth and metastasis. As such, this article aims to review study results which evaluated effects of cannabinoids from plant, synthetic and endogenous origins on cancer development in preclinical animal models and to examine the current standing of cannabinoids that are being tested in human cancer patients.
    URI
    http://hdl.handle.net/10342/7958
    Subject
    cannabinoids, cancer, in vivo, clinical studies, clinical trials, therapeutics, cancer models, endocannabinoids
    Date
    2016-07
    Citation:
    APA:
    Ladin, Daniel, & Soliman, Eman, & Griffin, LaToya, & Van Dross, Rukiyah. (July 2016). Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents. , (), - . Retrieved from http://hdl.handle.net/10342/7958

    Display/Hide MLA, Chicago and APA citation formats.

    MLA:
    Ladin, Daniel, and Soliman, Eman, and Griffin, LaToya, and Van Dross, Rukiyah. "Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents". . . (), July 2016. September 26, 2023. http://hdl.handle.net/10342/7958.
    Chicago:
    Ladin, Daniel and Soliman, Eman and Griffin, LaToya and Van Dross, Rukiyah, "Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents," , no. (July 2016), http://hdl.handle.net/10342/7958 (accessed September 26, 2023).
    AMA:
    Ladin, Daniel, Soliman, Eman, Griffin, LaToya, Van Dross, Rukiyah. Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents. . July 2016; (): . http://hdl.handle.net/10342/7958. Accessed September 26, 2023.
    Collections
    • Open Access

    xmlui.ArtifactBrowser.ItemViewer.elsevier_entitlement

    East Carolina University has created ScholarShip, a digital archive for the scholarly output of the ECU community.

    • About
    • Contact Us
    • Send Feedback